Formulation Forum

Using Gravitational Force to Determine the Minimum Concentration of Various Gelling Agents Needed to Maintain Homogeneity of Micronized API in Suspension Presented by Mary Magsombol-Karaan, Jonathan Behrs, Jose Viramontes, Jake Ridgway, Geneva Jump, Nkemdilim Ekomaye,...

Eliminating Operator Dependence from Gelling Agent Addition - Improving the Robustness and Processing Time of Semi-Solid Dosage Forms Without Impacting the Viscosity or Aesthetics Ruth Yu, Jason Carbol Dow Development Laboratories, LLC PURPOSE Aqueous gelling agents...

View/Zoom in to view the PDF below PURPOSE Development of topical...

View/Zoom in to view the PDF below PURPOSE With recent pharmaceutical trends in the application of...

Among the myriad steps involved in pharmaceutical product development, clinical labeling and packaging stand out as critical components that need special attention. Clinical trials are typically the most expensive part of the already costly and years long...

There are two times when forced degradation studies are needed when developing a stability-indicating method for the analysis of a drug product[1].  The first set of studies uses only the active pharmaceutical ingredient (API).  Since the goal of the method is to...

The creation of an analytical method for the measurement of the API and degradation products in a semisolid formulation happens in parallel with the creation of the product itself.  If the API is a repurposed drug substance, there is typically an existing method that...

PURPOSE Formulating aesthetically pleasing topical pharmaceuticals can pose a significant challenge with low water solubility drug substances. This can lead to the avoidance of water in topical formulations in order todissolve these hard to dissolve drugs. If the...

Critical Material Attributes (CMA) of Excipients in Topical Formulations: The Pitfalls of Switching Between Compendial Raw Materials Without a Full Analysis of all Critical Quality Attributes (CQA)   PURPOSE With the FDA introduction of Quality by Design (QbD) many...

Controlling the bacteria Burkholderia Cepacia Complex (BCC) in non-sterile pharmaceutical products has received increased attention in recent years.  BCC has now been classified as an “objectionable organism” by the industry and will need to be controlled...

The FDA Inactive Ingredient Database (IID) is heavily used by formulators when developing drug products.  This resource has been available since 19871 and has since informed the inactive ingredient (excipient) selections and concentrations made by formulation...

CMC is critical to a successful topical drug product program.  Important aspects of CMC that are unique to topical products are discussed in this presentation.

One of the most common issues faced during topical formulation development is difficulty in dissolving the active pharmaceutical ingredient (API) in water or other water-soluble solvent systems. When this happens, several approaches may be taken when trying to...

Proper scale up of a 1 kg batch to a 1,000+ kg batch takes engineering effort to execute properly.  Why is this so difficult?  The short answer is because of the math.  The physical forces on a semi-solid product while manufacturing a 1 kg laboratory batch vs. that of...

Pros and Cons of topical products containing a suspended API Prescription drug products contain an active pharmaceutical ingredient (API)1. While traditional topical drug product development focuses on dissolving the API, challenges can arise from dissolved systems....

Acneic skin can involve inflammation, comedones, excess sebum production and bacteria. Effective topical products for the treatment of acne must be designed with patient compliance in mind. Topical Formulations Made for Patients – Acne Products When developing topical...

Solubility determination of the active pharmaceutical ingredient (API) in excipients suitable for topical use is a key first step in formulation development. The objective of most topical formulations is to have dissolved API so that the API can most effectively move...

Nonsterile topical products must pass the USP/NF1 Microbial Examination of Nonsterile Products: Microbial Enumeration Tests <61> and Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms <62> and be adequately preserved. A...